Antibiotic research and development in pharmaceutical industry

Many pharmaceutical companies have abandoned their research for novel antibiotics in the last two decades. In addition, the antibiotics targeting Gram-negative infections currently in development have mechanisms very similar to those of drugs that are already available and used. Thus, there are only very few novel Gram-negative antibiotics in the pipeline that will work against bacteria already resistant to available drugs. However, in order to combat infections with MDR Gram-negative bacteria, novel antibiotics are urgently needed.